Bavdegalutamide

Bavdegalutamide
Clinical data
Other names	ARV-110
Identifiers
	IUPAC name N-[4-(3-chloro-4-cyanophenoxy)cyclohexyl]-6-[4-[[4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindol-5-yl]piperazin-1-yl]methyl]piperidin-1-yl]pyridazine-3-carboxamide;
CAS Number	2222112-77-6;
PubChem CID	134414307;
DrugBank	DB19032;
ChemSpider	110415899;
UNII	H6NYM0V650;
KEGG	D12316;
ChEMBL	ChEMBL4862963;
Chemical and physical data
Formula	C41H43ClFN9O6
Molar mass	812.30 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC(CCC1NC(=O)C2=NN=C(C=C2)N3CCC(CC3)CN4CCN(CC4)C5=C(C=C6C(=C5)C(=O)N(C6=O)C7CCC(=O)NC7=O)F)OC8=CC(=C(C=C8)C#N)Cl;
	InChI InChI=InChI=1S/C41H43ClFN9O6/c42-31-19-28(4-1-25(31)22-44)58-27-5-2-26(3-6-27)45-38(54)33-7-9-36(48-47-33)51-13-11-24(12-14-51)23-49-15-17-50(18-16-49)35-21-30-29(20-32(35)43)40(56)52(41(30)57)34-8-10-37(53)46-39(34)55/h1,4,7,9,19-21,24,26-27,34H,2-3,5-6,8,10-18,23H2,(H,45,54)(H,46,53,55); Key:CLCTZVRHDOAUGJ-UHFFFAOYSA-N;

Bavdegalutamide is an experimental proteolysis targeting chimera that functions as a androgen receptor degrader. It is being developed to treat metastatic castration-resistant prostate cancer.